Pharmacological treatment trials of agitation in Alzheimer’s disease: A systematic review of ClinicalTrials.gov registered trials

Abstract Introduction: There is increasing emphasis on the importance of optimizing and standardizing clinical trials of agitation in Alzheimer’s disease (AD), but the risks of bias arising from published trials and the number and design of unpublished studies are poorly understood. Methods: Using the ClinicalTrials.gov database, we systematically reviewed all registered investigational clinical trials for agitation in AD to describe the landscape of agitation drug treatment trials and to assess their quality and generalizability. Results: We included 52 clinical studies